Zevra Therapeutics, Inc.
ZVRA • NASDAQ
Zevra Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Neil F. McFarlane, with a market cap of $537.8M.
CEONeil F. McFarlane
Next Earnings
Upcoming earnings announcement for Zevra Therapeutics, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.07
Revenue Estimate
$31.7M
Earnings History
Past 12 earnings reports for Zevra Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Q4 2025 | $0.19Est: $0.05 | +280.0% | $34.1MEst: $28.0M | +21.9% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.01Est: -$0.03 | +66.7% | $26.1MEst: $26.6M | -2.0% | 10-Q |
| Aug 12, 2025 | Q2 2025 | $1.24Est: $1.40 | -11.4% | $25.9MEst: $22.5M | +14.9% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.06Est: -$0.19 | +68.4% | $20.4MEst: $17.0M | +20.3% | 10-Q |
| Mar 11, 2025 | Q4 2024 | -$0.67Est: -$0.40 | -67.5% | $12.0MEst: $8.9M | +34.4% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.69Est: -$0.42 | -64.3% | $3.7MEst: $4.9M | -24.1% | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.48Est: -$0.44 | -9.1% | $4.4MEst: $4.4M | +0.9% | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.40Est: -$0.48 | +16.7% | $3.4MEst: $3.8M | -8.9% | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.40Est: -$0.27 | -48.1% | $13.2MEst: $11.7M | +12.6% | — |
| Nov 7, 2023 | Q3 2023 | -$0.40Est: -$0.30 | -33.3% | $2.9MEst: $3.4M | -14.3% | — |
| Aug 14, 2023 | Q2 2023 | -$0.15Est: -$0.39 | +61.5% | $8.5MEst: $2.9M | +192.1% | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.34Est: -$0.23 | -47.8% | $2.9MEst: $2.7M | +8.6% | 10-Q |